Thrombolytic Science International

Executive Summary

Thrombolytic Science International (TSI) is a private, Phase 2-stage biopharmaceutical company dedicated to transforming the treatment of thrombotic diseases, particularly ischemic stroke. Founded in 2003 and headquartered in Cambridge, MA, TSI's core strategy is to develop an intravenous thrombolytic therapy that can be administered at the point of care, thereby overcoming the critical time-to-treatment barrier. By enabling early intervention, TSI aims to dramatically improve patient outcomes and access to life-saving therapy, moving beyond the current standard of care that requires transporting patients to specialized stroke centers. The company's focus on acute ischemic stroke addresses a massive unmet medical need, where every minute of delay reduces the chance of a good outcome.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Top-Line Data Readout65% success
• Q1 2027FDA End-of-Phase 2 Meeting80% success
• Q2 2027Series B Financing or Licensing Deal60% success